Abstract
COVID-19 is a contagious disease. Paxlovid, a combination of Nirmatrelvir and Ritonavir, was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID-19 on December 22, 2021. These are peptidomimetic coronavirus main protease inhibitors. Nirmatrelvir is a proline derivative. The present patent describes similar proline- like compounds, their preparation, use, pharmaceutical composition, and treatment.
Keywords: COVID-19, Proline derivatives, Protease inhibitors, Picornavirus, Norovirus, Single-stranded RNA virus
[http://dx.doi.org/10.1016/j.drudis.2020.12.005] [PMID: 33309533]
[http://dx.doi.org/10.1021/acsmedchemlett.2c00030] [PMID: 35291756]
[http://dx.doi.org/10.1038/s41598-022-13680-6] [PMID: 35688854]
[http://dx.doi.org/10.1136/bmj-2021-068302] [PMID: 34789505]
[http://dx.doi.org/10.1016/S0140-6736(20)30154-9] [PMID: 31986261]
[http://dx.doi.org/10.1001/jama.2020.12839] [PMID: 32648899]
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[http://dx.doi.org/10.3389/fmolb.2022.770775] [PMID: 35664675]
[http://dx.doi.org/10.1186/s11658-022-00339-3] [PMID: 35562685]
[http://dx.doi.org/10.1021/acs.jmedchem.2c00404]
[http://dx.doi.org/10.1016/j.cbi.2016.01.010] [PMID: 26776669]
[http://dx.doi.org/10.1016/j.molstruc.2017.10.075]